CA2101340A1 - Combination of igf-1 and igfbp for anabolism - Google Patents

Combination of igf-1 and igfbp for anabolism

Info

Publication number
CA2101340A1
CA2101340A1 CA002101340A CA2101340A CA2101340A1 CA 2101340 A1 CA2101340 A1 CA 2101340A1 CA 002101340 A CA002101340 A CA 002101340A CA 2101340 A CA2101340 A CA 2101340A CA 2101340 A1 CA2101340 A1 CA 2101340A1
Authority
CA
Canada
Prior art keywords
igf
combination
mammal
igfbp
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002101340A
Other languages
French (fr)
Other versions
CA2101340C (en
Inventor
Ross G. Clark
Venkat R. Mukku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Ross G. Clark
Venkat R. Mukku
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24624851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2101340(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ross G. Clark, Venkat R. Mukku, Genentech, Inc. filed Critical Ross G. Clark
Publication of CA2101340A1 publication Critical patent/CA2101340A1/en
Application granted granted Critical
Publication of CA2101340C publication Critical patent/CA2101340C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Abstract

A method is disclosed for producing an anabolic state in a mammal by co-admin-istration by subcutaneous injection of a combination of effective amounts of IGF-I
and an IGF binding protein in a defined molar ratio in the absence of growth hor-mone so as to produce a greater anabolic re-sponse in the mammal than that achieved using IGF-I alone in an amount equal to that used for IGF-I in the combination.
Preferably, the IGF-I is native-sequence, mature human IGF-I, the binding protein is IGFBP-3, and the mammal is human or a non-human animal of economic importance such as a cow or pig.
CA002101340A 1991-02-12 1992-01-13 Combination of igf-1 and igfbp for anabolism Expired - Lifetime CA2101340C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/654,436 1991-02-12
US07/654,436 US5187151A (en) 1991-02-12 1991-02-12 Use of binding protein with igf-i as an anabolic growth promoting agent
PCT/US1992/000345 WO1992013556A1 (en) 1991-02-12 1992-01-13 Combination of igf-i and igfbp for anabolism

Publications (2)

Publication Number Publication Date
CA2101340A1 true CA2101340A1 (en) 1992-08-13
CA2101340C CA2101340C (en) 2003-05-06

Family

ID=24624851

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002101340A Expired - Lifetime CA2101340C (en) 1991-02-12 1992-01-13 Combination of igf-1 and igfbp for anabolism

Country Status (10)

Country Link
US (1) US5187151A (en)
EP (1) EP0571417B1 (en)
JP (1) JPH06505235A (en)
AT (1) ATE135587T1 (en)
CA (1) CA2101340C (en)
DE (1) DE69209277T2 (en)
DK (1) DK0571417T3 (en)
ES (1) ES2085001T3 (en)
GR (1) GR3019851T3 (en)
WO (1) WO1992013556A1 (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374620A (en) * 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5407913A (en) * 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
EP0661990B1 (en) * 1992-08-26 2002-04-10 Celtrix Pharmaceuticals, Inc. Method for systemic treatment of catabolic conditions and systemic tissue injury
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
MD1486G2 (en) * 1992-10-29 2001-11-30 Genentech, Inc. Method for treatment or prevention of obesity
JPH08504763A (en) * 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド Use of TGF-β receptor fragment as a therapeutic agent
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
EP0686040A1 (en) * 1993-01-29 1995-12-13 Amgen Boulder Inc. Wound healing composition
US5459051A (en) * 1993-03-26 1995-10-17 Celtrix Pharmaceuticals, Inc. Methods and vectors for over-expression of ubiquitin fusion proteins in host cells
ATE226958T1 (en) * 1993-09-20 2002-11-15 Celtrix Pharma TREATMENT OF HEMATOLOGICAL DISORDERS WITH AN IGF-1/IGFBP-3 COMPLEX
CA2176708A1 (en) * 1993-11-15 1995-05-26 Christopher A. Maack Method of treating neurological disorders
US5824642A (en) * 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
EP0800530A4 (en) * 1994-07-20 1998-12-02 Celtrix Pharma Igf/igfbp complex for promoting bone formation and for regulating bone remodeling
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AUPN271195A0 (en) * 1995-05-02 1995-05-25 Bunge Meat Industries Ltd. Method of selecting livestock
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
EP0766966A3 (en) * 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
US5948757A (en) * 1996-03-01 1999-09-07 Celtrix Pharmaceuticals, Inc. High dose IGF-1 therapy
US5747273A (en) * 1996-05-07 1998-05-05 Diagnostic Systems Laboratories, Inc. Immunoassay of total insulin-like growth factor binding protein-1
AUPN999096A0 (en) * 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6066464A (en) * 1996-12-10 2000-05-23 Diagnostic Systems Laboratories, Inc. Immunoassay of IGF family of peptides, their binding proteins and related molecules in dried whole blood filter paper spots
US5824467A (en) * 1997-02-25 1998-10-20 Celtrix Pharmaceuticals Methods for predicting drug response
US6514937B1 (en) * 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
DE69835878T2 (en) * 1997-05-05 2007-04-26 Mayo Foundation For Medical Education And Research, Rochester IGFIIE / IGFBP2 complex
US6548482B1 (en) 1997-05-05 2003-04-15 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
US6916790B2 (en) 1997-05-05 2005-07-12 Mayo Foundation For Medical Education And Research Treatment of osteoporosis
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US6436897B2 (en) * 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US7288516B1 (en) 1999-09-20 2007-10-30 Celtrix Pharmaceuticals, Inc. Null IGF for the treatment of cancer
WO2000020024A2 (en) * 1998-10-02 2000-04-13 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
PT1141014E (en) * 1999-01-06 2005-04-29 Genentech Inc VARIATION OF THE INSULIN-LIKELY GROWTH FACTOR (IGF-I)
EP1282437B1 (en) 2000-05-16 2008-03-19 Genentech, Inc. Treatment of cartilage disorders
AU9109001A (en) * 2000-09-19 2002-04-02 Bioexpertise Llc Method for use of IGF-binding protein for selective sensitization of target cells in vivo
AUPR030900A0 (en) * 2000-09-22 2000-10-12 Queensland University Of Technology Growth factor complex
HUP0500733A3 (en) * 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US6887851B2 (en) * 2001-09-18 2005-05-03 Bioexpertise, Llc IGF-binding protein-derived peptide
JP4344242B2 (en) * 2001-09-18 2009-10-14 バイオエキスパータイズ， エルエルシー Peptides or small molecules derived from IGF binding proteins
US6914049B2 (en) * 2001-09-18 2005-07-05 Bioexpertise, Llc IGF-binding protein-derived peptide or small molecule
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
AU2005279758A1 (en) * 2004-08-30 2006-03-09 Tercica, Inc. Method and device for diagnosing and treating insulin-like growth factor deficiency disorders
US8518877B2 (en) * 2007-04-18 2013-08-27 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
US20190018025A1 (en) * 2015-12-31 2019-01-17 Siemens Healthcare Diagnostics Inc. Non-recombinant human insulin-like growth factor binding protein concentrate
US10212614B2 (en) * 2015-12-31 2019-02-19 Facebook, Inc. Igniting network nodes in a multi-hop wireless network

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1163880B (en) * 1983-07-29 1987-04-08 Guido Vergari BINDING CLAMP
US5077276A (en) * 1985-08-22 1991-12-31 Gropep Pty Ltd Growth factor
JP2648951B2 (en) * 1987-04-06 1997-09-03 セルトリックス ファーマシュウティカルズ，インク Human somatomedin carrier protein subunits and methods for their production
DK131988A (en) * 1988-03-11 1989-09-12 Erasmus University IGF BINDING PROTEIN, DNA STRUCTURE CODING FOR IGF BINDING PROTEIN AND VECTOR CONTAINING THIS DNA STRUCTURE
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
AU1955388A (en) * 1988-04-12 1989-11-03 Synergen, Inc. Method for potentiating and inhibiting insulin-like growth factor activity
DE3822646A1 (en) * 1988-07-05 1990-01-11 Steag Ag METHOD FOR OBTAINING SPHERICAL SOLIDS PARTICULAR, IN PARTICULAR, FOR USE AS BEAM BEAMS
EP0424416B1 (en) * 1988-07-15 1995-07-19 Central Sydney Area Health Service Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex
GB8826451D0 (en) * 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides

Also Published As

Publication number Publication date
DE69209277T2 (en) 1996-10-31
WO1992013556A1 (en) 1992-08-20
EP0571417A1 (en) 1993-12-01
ES2085001T3 (en) 1996-05-16
JPH06505235A (en) 1994-06-16
DK0571417T3 (en) 1996-04-15
DE69209277D1 (en) 1996-04-25
EP0571417B1 (en) 1996-03-20
US5187151A (en) 1993-02-16
GR3019851T3 (en) 1996-08-31
ATE135587T1 (en) 1996-04-15
CA2101340C (en) 2003-05-06

Similar Documents

Publication Publication Date Title
CA2101340A1 (en) Combination of igf-1 and igfbp for anabolism
CA2083159A1 (en) The combination of growth hormone and insulin-like growth factor-1 enhances growth
GR3024128T3 (en) Method of stimulating immune response.
MD1558F2 (en) Method of prophylaxis of mammal acute renal insufficiency utilizing IGF-I insulin-like growth factor
Singhas et al. Hormonal control of the tail fin and of the nuptial pads in the male red-spotted newt
EP0660719A4 (en) Method and composition for ameliorating tissue damage due to ischemia and reperfusion.
GB8707117D0 (en) Adjusting commencement in fuel injection pump
O’Callaghan et al. Effect of exogenous thyroxine on timing of seasonal reproductive transitions in ewes
EP0356107A3 (en) Proteins having growth hormone anabolic properties with reduced effect on carbohydrate metabolism
NZ219530A (en) Composition and method for enhancing growth of mammary parenchyma
AU2085392A (en) Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
IL99920A0 (en) Controlled release delivery of growth hormone to non-human animals
WO1989000166A3 (en) Growth hormone related peptide
Dawson Pharmacological doses of thyroxine simulate the effects of increased daylength, and thyroidectomy, decreased daylength on the reproductive system of European starlings
MY100892A (en) Veterinary preparations.
AP Almeida Seasonal variations in the superovulatory responses to PMSG in dairy cows
EP0104933A3 (en) Somatomedin growth promoter
AU6461590A (en)
EP0362999A3 (en) Improved carcass quality
Deshpande et al. Periovulatory endocrine profile in Murrah buffaloes under two superovulatory regimes
GB9324167D0 (en) Synergistic combination to improve the secretion of endogenous growth hormone
Barnum Thyroid hormone, growth hormone and prolactin interactions in the regulation of growth in the rat
GB1165776A (en) Animal Feed Supplements
BG47124A1 (en) Method for growth of monocrystalline gallium arsenide alloyed in isovalent manner with indium
MX9803316A (en) Process for the preparation of a growth hormone secretagogue.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry